Jeongmin Lee

Dr. Jeongmin Lee

DVM
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Journal of Veterinary Internal Medicine
Verified
Journal Article
Open access
JLJeongmin Lee
Jeongmin Lee
KYKyoung-A Youp
Kyoung-A Youp
SLSun-Tae Lee
Sun-Tae Lee
ALAh-Ra Lee
Ah-Ra Lee
YCYoung-Wook Cho
Young-Wook Cho
SLSeung-Keun Lee
Seung-Keun Lee
Background: Transcatheter edge-to-edge repair (TEER) is an emerging minimally invasive mitral valve repair treatment for dogs with myxomatous mitral valve disease (MMVD), but reports on its outcomes are limited. Objective: Describe the clinical characteristics and complications in dogs with MMVD undergoing TEER. Animals: Twenty client-owned dogs with MMVD stages B2, C, and D. Methods: Retrospective case series. Cases were identified by review of hospital medical records between September 2023 and September 2024. Results: Twenty dogs underwent TEER; of these, 13 (65%) survived. Seven dogs died within 9 days because of mitral leaflet tear or single-leaflet device attachment (4/7 dogs, 57.1%), tracheal collapse (1/7 dogs, 14.3%), presumed post-procedure neurologic deficit with a history of hydrocephalus (1/7 dogs, 14.3%), and presumed cardiogenic shock (1/7 dogs, 14.3%). Significant reductions in vertebral heart score (11.6 [9.6–13.1] vs. 11.0 [8.3–11.9] vertebrae; p < 0.01), vertebral left atrial size (2.90 [2.1–3.6] vs. 2.60 [2.0–3.3] vertebrae; p < 0.01), left atrium-to-aortic root ratio (2.09 [1.5–2.5] vs. 1.69 [1.3–2.2]; p < 0.05), left ventricular end-diastolic diameter normalized for body weight (2.1 [1.5–2.3] vs. 1.76 [1.4–2.2]; p < 0.05), regurgitant fraction (77.83 [73.2–83.0] vs. 55.38 [20.5–73.6] %; p < 0.05), and regurgitant volume (3.96 [2.1–6.2] vs. 1.25 [0.4–3.5] ml/kg; p < 0.05) were observed 3 months after TEER. Conclusions and Clinical Importance: Transcatheter edge-to-edge repair resulted in a significant reduction in left atrium and ventricle size and should be further investigated as a potential treatment option for dogs with MMVD.

18 August 2022 in Toxins
Verified
Journal Article
Open access
PDF file
JLJeongmin Lee
Jeongmin Lee
JSJoong-Hyun Song
Joong-Hyun Song
KSKun-Ho Song
Kun-Ho Song
Snake envenomation is a medical emergency capable of causing local and systemic complications. However, information on venomous snakebite in dogs in South Korea is scarce. In this study, fifty-nine dogs treated at a private veterinary clinic from 2004 to 2021 were retrospectively studied. The aim was to characterize the demographics, elapsed time between snakebite and veterinary clinic presentation, laboratory findings, clinical signs, treatments, adverse reactions to antivenom, and prognosis of venomous snakebite. Snakebite was mostly observed between 12 p.m. and 5 p.m. from April to October. On the days of envenomation, the weather conditions were mostly cloudy, followed by rain/precipitation, and least frequently fair weather. Grassland was the most common incident location, and leashed dog walking was the most frequent activity when snakebite occurred. The main local symptoms were edema, hemorrhagic discharge, cutaneous erythema, ulceration, and necrosis. Major systemic clinical signs were tachypnea, tachycardia, altered mentation, ptyalism, and hypotension. Based on the time interval between snakebite and presentation at the veterinary clinic, two groups were defined: <4 h (Group 1, 49.2%) and ≥4 h (Group 2, 50.8%). Systemic inflammation was more frequently observed in Group 2. The level of C-reactive protein at presentation (p = 0.036) and the highest-level during hospitalization (p = 0.023) were significantly elevated in Group 2 (≥4 h). The dogs in Group 2 displayed more frequent muscle damage (increased creatine kinase) than the dogs in Group 1, and a higher level of creatine kinase was associated with delayed (≥4 h) presentation after snakebite (p = 0.003). All of the dogs were treated symptomatically, and 34 dogs (58%) received antivenom. Treatment with antivenom showed no adverse reactions in this study. All of the treated dogs recovered. One dog was euthanized without any treatment due to respiratory distress, hypotension, and cost constraints. In conclusion, this study provides baseline information on venomous snakebite in dogs in South Korea. The prognosis was excellent, especially when the dogs were treated within 4 h.

2 March 2025 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
JLJeongmin Lee
Jeongmin Lee
SLSeung-Keun Lee
Seung-Keun Lee
KYKyoung-A Youp
Kyoung-A Youp
ALAh-Ra Lee
Ah-Ra Lee
YCYoung-Wook Cho
Young-Wook Cho
SLSun-Tae Lee
Sun-Tae Lee
Myxomatous mitral valve disease (MMVD) in dogs can be treated with transcatheter edge-to-edge mitral valve repair (TEER), an emerging minimally invasive surgical technique. However, reports on prognostic markers for preoperative evaluation remain limited. This study evaluated the association of preoperative N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac troponin I (cTnI) levels with procedure safety in dogs undergoing TEER. A retrospective analysis was conducted on 25 dogs diagnosed with stage C (n = 18) or D (n = 7) MMVD that underwent TEER between September 2023 and January 2025. Preoperative NT-proBNP and cTnI values were measured and compared between survivors and non-survivors. Among the survivors, 15 and 4 dogs were stages C and D, respectively. Among the non-survivors, three and three dogs were stages C and D, respectively. Non-survivors had higher median NT-proBNP levels (3557 pmol/L; range: 774–10,000) and cTnI levels (0.39 ng/mL; range: 0.22–0.51) than survivors (NT-proBNP: 1262.6 pmol/L, range: 500–8773; cTnI: 0.1 ng/mL, range: 0.01–3.6). However, the two groups showed no significant differences in NT-proBNP (p = 0.187) or cTnI (p = 0.869). Increased preoperative NT-proBNP and cTnI levels were not strong predictors of procedure safety in dogs with MMVD stages C and D undergoing TEER. Further studies with larger sample sizes and longer follow-up periods are needed to better evaluate the prognostic value of these biomarkers in this population.

31 December 2023 in Journal of Veterinary Clinics
Verified
Journal Article
Open access
PDF file
JHJihee Hong
Jihee Hong
JLJeongmin Lee
Jeongmin Lee
JLJiyoung Lee
Jiyoung Lee
HLHan-Joon Lee
Han-Joon Lee
DLDong-Kwan Lee
Dong-Kwan Lee
KSKun-Ho Song
Kun-Ho Song
Jihee Hong, Jeong-Min Lee, Ji-Young Lee, Han-Joon Lee, Dong-Kwan Lee, Joong-Hyun Song, Kun-Ho Song. J Vet Clin 2023;40:445-51. https://doi.org/10.17555/jvc.2023.40.6.445

28 December 2023 in Korean Journal of Veterinary Research
Verified
Journal Article
Open access
PDF file
HPHee-Tae Park
Hee-Tae Park
JLJeongmin Lee
Jeongmin Lee
HBHyeona Bae
Hyeona Bae
DYDo-Hyeon Yu
Do-Hyeon Yu
Dong-In JungDong-In Jung
Dong-In Jung
JSJoong-Hyun Song
Joong-Hyun Song
Canine T-zone lymphoma (TZL) is an indolent form of T-cell lymphoma. Conservative management is usually recommended; however, chemotherapy may be considered for symptomatic or progressive cases. Herein, we describe two dogs with generalized peripheral lymphadenopathy and peripheral blood lymphocytosis at presentation. One dog presented with gross lesions on the tongue. Flow cytometric immunophenotyping and cytological examinations demonstrated findings consistent with those of TZL. Chemotherapy with chlorambucil and prednisolone was administered, which resulted in improvement of the condition without any adverse events. Chemotherapy with chlorambucil may be considered as an appropriate choice for treating canine TZL.

1 December 2024 in American Journal of Veterinary Research
Verified
Journal Article
Open access
PDF file
JLJeongmin Lee
Jeongmin Lee
SLSeungkeun Lee
Seungkeun Lee
KSKunho Song
Kunho Song
SESamantha Evans
Samantha Evans
JHJiwoong Her
Jiwoong Her
OBJECTIVE: To investigate the level of whole-blood ionized magnesium (iMg) in dogs with long-term use of proton pump inhibitors (PPIs). METHODS: The study included 10 client-owned dogs with esomeprazole administration over 6 months and 62 healthy dogs to determine de novo reference interval (RI) of iMg. Dogs that received esomeprazole for 6 months or longer were retrospectively reviewed to determine the incidence of hypo- or hypermagnesemia based on the de novo RI. Additionally, the iMg levels from the study group were compared with those of 20 age-, sex-, and body weight–matched controls from the 62 dogs. RESULTS: The median (range) duration of esomeprazole usage was 26 months (6 to 94). The de novo RI for iMg was determined as 0.73 (90% CI, 0.58 to 0.87) to 1.43 mg/dL (90% CI, 1.33 to 1.46). Based on the RI, none of the dogs with long-term esomeprazole developed hypo- or hypermagnesemia. The iMg from the matched control group was 1.17 mg/dL (90% CI, 0.83 to 1.46). The lowest iMg after 6 months of esomeprazole administration (90% CI, 0.96 mg/dL, 0.87 to 1.41) was significantly lower than the control group (P = .031). The iMg measured at the end of long-term esomeprazole treatment was 1.03 mg/dL (90% CI, 0.87 to 1.41) and not significantly different from the control group (P = .179). CONCLUSIONS: Ionized hypomagnesemia was not observed after long-term use of esomeprazole in the small number of dogs included in this study. Robust RI needs to be determined in future studies to investigate the incidence of hypomagnesemia in dogs with long-term use of PPIs. CLINICAL RELEVANCE: Future studies in a larger number of dogs are warranted to confirm the findings from the present study and to determine whether the long-term use of esomeprazole in dogs is at risk of developing ionized hypomagnesemia.